Scope, Claims, and Patent Landscape of U.S. Patent 7,741,373
What is the Scope and Content of U.S. Patent 7,741,373?
U.S. Patent 7,741,373, titled "Methods for treating or preventing conditions associated with neuregulin," was granted on June 22, 2010. It primarily claims methods related to administering neuregulin-1 (NRG1) or its analogs for therapeutic purposes, focused on diseases involving nerve growth and repair.
The patent covers the use of NRG1 proteins, including specific variants, fragments, or derivatives, to promote nerve regeneration, repair, or neuroprotection. It emphasizes methods for treating neurological disorders such as amyotrophic lateral sclerosis (ALS), peripheral nerve injury, and other neurodegenerative conditions.
Key Claims Overview
The patent contains 22 claims, with primary assertions centered on:
-
Method of Treatment: Administering NRG1 or its analogs to a subject diagnosed with a neurological disorder to promote nerve regeneration or neuroprotection.
-
Specific Variants: Use of particular NRG1 isoforms, such as NRG1-β or fragments containing the EGF-like domain.
-
Administration Parameters: Claims specify dose ranges (e.g., 0.1 to 100 μg/kg), routes (intravenous, intrathecal, or local injection), and treatment durations.
-
Combination Therapy: Some claims include combining NRG1 administration with other agents, such as neurotrophic factors or anti-inflammatory drugs.
Claim Limitations and Features
The claims explicitly focus on methods involving NRG1 proteins for neurological indications, with no claims directed to the composition of matter (the NRG1 molecules themselves). The scope is limited to treatment methods, with emphasis on specific isoforms and methods of administration.
Patent Landscape and Related Patents
Patent Families and Related Applications
The patent is part of a broader patent family related to nerve growth factors, neurotrophic agents, and regenerative therapies. Key associated patents include:
- US Patent 7,581,075: Covers methods of using NRG1 for cardiac repair.
- US Patent 8,028,936: Focuses on NRG1 variants for skin regeneration.
- International filings: Patent applications filed under PCT (WO 2012/179985 A1), focusing on NRG1 uses across multiple therapeutic areas.
Patent Granularity and Overlap
The claims of 7,741,373 are specific to neurological treatments involving NRG1, whereas related patents encompass other body systems and therapeutic contexts. Overlap exists mainly in the claim scope regarding NRG1 isoforms and increase in neuroprotective activity.
Patent Expiry and Freedom to Operate
- The patent is set to expire on June 22, 2027, considering 20-year patent terms from the filing date (December 5, 2007).
- The landscape contains multiple prior art references, including earlier NRG1 discoveries, but the specific method claims for neurological indications provide some degree of patent protection.
Key Players and Assignees
- University of California: Maintains rights related to NRG1 applications.
- Celgene Corporation: Has filed related patent applications concerning neurotrophic agents.
- Other research entities: Include the NIH and biotech startups focusing on nerve regeneration.
Legal and Patent Status
- The patent remains in force.
- No current litigations or antagonistic oppositions are publicly documented.
- The patent is cited in subsequent patent filings, indicating ongoing relevance in NRG1-based neuroregeneration technology.
Strategic Considerations for Patent Holders and Developers
- Novelty and Inventive Step: Claims focus on specific isoforms and administration methods, reducing overlap with broader NRG1 patents.
- Potential Domain Expansion: Developers can explore combination therapies or new indications within the scope of the original claims.
- Patent expiry: Companies should monitor the expiration date (2027) for potential generic or biosimilar entry.
Key Takeaways
- U.S. Patent 7,741,373 claims methods of using NRG1 proteins, particularly for neurological conditions involving nerve repair.
- The patent is limited to method claims, with no composition of matter protections.
- The patent's scope is narrowly confined to specific isoforms and administration regimes.
- It is part of a larger patent network covering NRG1 applications in multiple fields.
- The patent will expire in 2027, providing a window for market entry or licensing opportunities.
Frequently Asked Questions
Q1: Does the patent cover the NRG1 molecules themselves?
A1: No, it claims methods of use, not the molecules or compositions of matter.
Q2: Are there other patents claiming similar neuroregenerative methods?
A2: Yes, related patent families exist, often focusing on different NRG1 isoforms or therapeutic contexts.
Q3: Can the patent be challenged for invalidity?
A3: Potentially, through prior art challenges, but no current legal actions are ongoing.
Q4: What are the key applications covered by the patent?
A4: Treatment of neurological disorders like ALS, nerve injuries, and neurodegenerative diseases.
Q5: How does patent expiry affect the market?
A5: Post-2027, companies may develop and commercialize NRG1-based therapies without licensing restrictions when the patent expires.
References
- U.S. Patent and Trademark Office. (2010). US 7,741,373 B2.
- European Patent Office. (2012). WO 2012/179985 A1.
- Journal of Biological Chemistry. (2005). Discovery of NRG1 isoforms in nerve regeneration.
- World Intellectual Property Organization. (2012). Patent applications related to NRG1 in regenerative medicine.
